Top Software Startups in 2027

A world where businesses operate with clarity, speed, and precision powered by technology that adapts to change, strengthens decision-making, and supports sustainable growth. We aim to be the partner companies’ trust when they’re ready to evolve their digital infrastructure and build smarter systems that last.

SLSCRW helps deeptech companies turn great technology into commercial traction. A lot of deeptech companies have the same problem. They have strong technical teams, promising technology and a market that should exist, but building a full commercial team too early is expensive and often makes little sense. Sales in deeptech also comes in waves. You may need serious commercial firepower for six months, then much less for the next six. That is what SLSCRW is built for. We act as a shared commercial team for deeptech companies. We help figure out where the real commercial opportunity is, identify the companies and people worth pursuing, open the right conversations and keep opportunities moving until there is something real on the table. We focus on sectors where selling requires technical understanding, patience and access to the right people: semiconductors, AI and computing, photonics, robotics, energy and storage, advanced materials, industrial biotech, space and other deeptech markets. Companies can use us when they need us and scale us down when they do not. Because our people, tools and network are shared across several companies, we can provide senior commercial capability without every company having to build the same infrastructure itself. And sometimes we go one step further. For companies we strongly believe in, SLSCRW can invest part or even all of our work instead of charging the full fee in cash. That means our upside can be tied to the value we help create. We are building SLSCRW around a simple idea: deeptech companies should be able to access world-class commercial capability as flexibly as they access other critical infrastructure. Build the technology. We help make sure someone buys it.

Pear Growth is a tech-first TikTok Shop agency in London. We are a registered TikTok Shop Partner, recognised by TikTok as a top five TikTok Shop Partner for FMCG. Our own software does the repetitive work, so our team spends its time on strategy, creators and LIVE. The agency We help UK brands grow sales on TikTok Shop through affiliate creator campaigns, TikTok LIVE shopping from our London studio, GMV Max and Spark Ads, and day-to-day shop management. Published results include The Antidotes (£888,731 in revenue), Qleen (£0 to £5k a day in 60 days with no ad spend), Vita Bright (£43,160 in revenue in 60 days from a cold start) and Ballers Bank UK (£132,043 in GMV from TikTok LIVE in 9 weeks). Lumo, our platform Lumo (lumoplatform.ai) is the software behind the agency, and brands can also use it directly. It runs a creator affiliate programme end to end. FitScore ranks 500,000+ indexed creators by predicted conversion for a product. Outreach goes out with automatic follow-ups until creators reply. A nine-stage pipeline tracks every creator and sample from first contact to revenue, and an AI strategist flags what changed and what to do next. Agentic builds We are also building AI agent systems that run the day-to-day work of a TikTok Shop for a brand, from creator activation and samples to reporting and ad checks, with a person approving each change. Brands can have us run the system for them as a managed service, or license it to run in their own stack. Who we are Our co-founders are Tom Stanley, a former TikTok employee, Chartered Accountant and Chartered Tax Adviser, and Sahil Patel. We are a small team that sits where agency operations and product meet: the people building Lumo and our agents work alongside the people running client shops every day.

Clarapath is a medical robotics company automating the laboratory. The company's first product is focused on fully automating the microtomy station in pathology. Their vision is to innovate, standardize, and digitally transform anatomic pathology through higher-quality lab medicine, more robust safety standards, and increased lab throughput while lowering laboratory costs and labor-related delays. Their next-generation laboratory at the NY Genome Center together with our large-scale image repository and analysis platform are designed to handle the entire “tissue to bits” pipeline for special research projects as well as larger-scale clinical needs. Clarapath works closely with both research and clinical customers to produce faster, more accurate results.